Cingulate Announces Adjournment of Extraordinary Meeting

KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company leveraging its proprietary Precision Timed Release (PTR) drug delivery technology to build and develop a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its extraordinary meeting of shareholders (the “Special Meeting”) to provide shareholders with additional time to vote on all proposals.

At this time, there are not, by remote communication or by proxy, sufficient shares of the Company’s ordinary share capital present to constitute a quorum. The Company’s Board of Directors continues to believe that all proposals contained in the proxy statement are advisable and in the best interests of the Company’s shareholders to consider and act upon. Accordingly, the Company has adjourned the Extraordinary Meeting.